Spark Therapeutics joins the skyline of Philadelphia

News & events

Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor

Read More read more

Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A

Read More read more

Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders

Read More read more

Get our news alerts delivered straight to your inbox

Subscribe Now

We don’t follow footsteps. We create the path.℠

Our mission at Spark Therapeutics is to unlock the power of gene therapy to accelerate healthcare transformation. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-directed diseases such as hemophilia, and neurodegenerative diseases.

Learn More